Ivacaftor sales will expand through 2036, with tablets at 74.0% of the form category and ≥99.5% at 62.0% of purity grade demand in 2026. The market is estimated at USD 580.9 million in 2026, is projected to reach USD 923.4 million by 2036 and is forecast to record a 4.7% CAGR between 2026 and 2036.